What's Happening?
A large-scale collaborative project is underway to perform whole exome sequencing on nearly 75,000 blood samples from the Multiethnic Cohort (MEC) Study. This initiative involves researchers from the Keck School of Medicine of USC and the University of Hawaiʻi,
in partnership with the Regeneron Genetics Center (RGC). The goal is to enhance the precision of cancer risk assessment across diverse populations by identifying rare genetic variations that influence cancer development. The MEC Study, which began in 1993, is a long-term investigation into cancer and chronic disease with over 215,000 participants from Southern California and Hawaiʻi, representing various ethnic backgrounds including African Americans, Japanese Americans, Latinos, Native Hawaiians, and white individuals. This project moves beyond previous genome-wide association studies (GWAS) by focusing on whole exome sequencing, allowing for a more comprehensive analysis of genetic factors. Researchers will also assess copy number variation and explore whether known genetic variants for one cancer type contribute to others. The sequencing phase is expected to conclude by 2027, followed by extensive data analysis.
Why It's Important?
This project is crucial for addressing a significant limitation in genetic epidemiology: the historical reliance on less diverse data for cancer risk models. By including a wide range of ethnic groups, the initiative aims to create more robust and universally applicable risk predictions, moving away from the assumption that a single population's risk profile is universal. This enhanced understanding of genetic architecture across diverse populations will lead to more precise screening and prevention efforts, ultimately improving health outcomes for a broader patient base in the U.S. The collaboration with the Regeneron Genetics Center provides essential technical infrastructure and computational capacity, enabling the generation of rich, actionable insights into human biology. The findings, while observational, will describe associations between genetic variations and health outcomes, laying groundwork for future clinical applications and advancements in cancer prevention and treatment.
What's Next?
The sequencing phase of the project is slated for completion by 2027. Following this, researchers will embark on the complex task of data analysis, which will involve interpreting the vast amount of genetic information gathered from the 75,000 diverse samples. The findings will describe associations between genetic variations and health outcomes, rather than establishing direct clinical causation. This observational data will be critical for informing future research directions and potentially guiding the development of more targeted cancer risk assessment tools. The scalability of this effort also positions the USC team to participate in larger consortium studies, combining the MEC dataset with other cohorts and biobanks to achieve the statistical power needed to study extremely rare variants and establish definitive links to cancer risk.
Beyond the Headlines
The project's emphasis on genomic diversity has profound implications for precision medicine equity. Historically, predictive risk models have been biased due to data primarily from populations of European ancestry, leading to potential disparities in cancer risk assessment and prevention strategies for other ethnic groups. By actively seeking to understand genetic variations across a multiethnic cohort, this initiative directly addresses these disparities, aiming to ensure that future genetic insights and clinical tools are equitable and effective for all. This shift represents a significant step towards democratizing genomic medicine, ensuring that advancements in cancer prevention and treatment are accessible and relevant to the diverse U.S. population. The long-term impact could be a more inclusive healthcare system where genetic risk assessments are tailored to an individual's ancestral background, leading to more personalized and effective interventions.













